Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist-Reference-Cited by-同舟云学术

Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist

Published:2017-04-17 Issue:8 Volume:60 Page:3405-3421
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Hunt Hazel J.¹^ORCID,Belanoff Joseph K.¹,Walters Iain²,Gourdet Benoit²,Thomas Jennifer²,Barton Naomi²,Unitt John²,Phillips Timothy²,Swift Denise²,Eaton Emily²

Affiliation:

1. Corcept Therapeutics, 149 Commonwealth Drive, Menlo Park, California 94025, United States

2. Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham, NG1 1GF, U.K.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b00162

Reference23 articles.

1. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation.

2. The human glucocorticoid receptor: One gene, multiple proteins and diverse responses